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ABSTRACT
Renal osteodystrophy (ROD) is a heterogeneous group of meta-
bolic bone diseases complicating progressive chronic kidney
disease (CKD). Bone biomarkers and bone imaging techniques
may help to assess bone health and predict fractures in CKD but
do have important inherent limitations. By informing on bone
turnover and mineralization, a bone biopsy may help to guide
prevention and treatment of ROD and its consequences.
According to a recent survey conducted among European neph-
rologists, bone biopsies are performed rather exceptionally,
both for clinical and research purposes. Obviously, clinical
research in the ﬁeld of ROD is threatened by vanishing clinical
and pathological expertise, small patient cohorts and scientiﬁc
isolation. In March 2016, the European Renal Osteodystrophy
(EU-ROD) initiative was created under the umbrella of the
ERA-EDTA CKD-mineral and bone disorder (MBD) Working
Group to revitalize bone biopsy as a clinically useful tool in the
diagnostic workup of CKD-MBD and to foster research on the
epidemiology, implications and reversibility of ROD. As such,
the EU-ROD initiative aims to increase the understanding of
ROD and ultimately to improve outcomes in CKD patients.
Keywords: biomarkers, bone mineral density, chronic renal
failure, hyperparathyroidism, renal osteodystrophy
INTRODUCTION
Renal osteodystrophy (ROD) is a heterogeneous group of meta-
bolic bone diseases that accompanies progressive chronic kid-
ney disease (CKD). These metabolic bone diseases have
specifically defined quantitative histomorphometric diagnostic
criteria as well as clinical features [1]. More recently, the Kidney
Disease: Improving Global Outcomes (KDIGO) Working
Group offered a new and more encompassing definition of
renal bone disease, i.e. CKD-mineral and bone disorder (MBD)
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|[2]. This more general definition recognizes that the patho-
physiology of renal bone disease extends beyond the skeleton
and that there are links between abnormal bone remodelling
activity and the risk for soft tissue and vascular calcification
(commonly referred to as the bone–vascular axis). In this new
construct, the term ROD is limited to the specific changes in
bone histology seen in CKD. Besides playing a crucial role in
locomotion, the skeleton is increasingly recognized as an endo-
crine organ capable of producing various hormones involved in
energy, glucose and mineral metabolism [3]. Thus the bone
may be not only a target but also a driver of mineral disturban-
ces in CKD.
Clinical research in the field of ROD lags behind and is
threatened by vanishing clinical and pathological expertise in
bone biopsy retrieval and reading, small patient cohorts and sci-
entific isolation. ROD, however, is not innocent, as it may result
in fractures, bone pain, deformities in growing children,
reduced growth velocity/peak bone mass and abnormal height
and indirectly to vascular calcification and increased (cardiovas-
cular) mortality [1, 4]. Bone biomarkers [5] and bone imaging
techniques [dual-energy X-ray absorptiometry (DXA), mag-
netic resonance imaging (MRI), high-resolution peripheral
quantitative computed tomography (HR-pQCT), 18F-fluoride
positron emission tomography, etc.) may help to assess bone
health and predict fractures in CKD, but do have important
inherent limitations. A bone biopsy, performed after tetracy-
cline labelling, allows definitive assessment of the material and
structural characteristics that contribute to bone quality and
hence to bone strength [6]. Several complementary analytical
techniques can be applied, including microscopy (histomorph-
ometry and immunohistochemistry), imaging techniques, spec-
trometry and molecular diagnostics [7]. In daily clinical
practice, a bone biopsy may greatly facilitate clinical decision
making by informing on bone turnover and mineralization.
Patients with CKD are at increased risk of fractures. The
fracture risk steadily increases along the progression of renal
disease to become four times higher in end-stage renal disease
patients than in non-renal counterparts [8]. The risk further
increases, at least transiently, following renal transplantation
[9]. Compared with those without fractures, patients with CKD
experience a multifold increased risk of mortality [10].
Both a high fall risk [11] and impaired bone strength account
for the increased fracture risk in CKD. Bone strength is deter-
mined by bone quantity and bone quality. Several lines of evi-
dence indicate that CKD is a state of low bone mass and
accelerated bone loss [12]. Bone mass can be evaluated non-
invasively by imaging techniques such as DXA and pQCT. It is
increasingly acknowledged that, similar to the general popula-
tion, low bone mineral density (BMD) predicts fracture risk in
CKD. Since adjustment for bone mineral density (BMD) does
not nullify the association between CKD and increased fracture
risk, CKD may be equally considered a state of impaired bone
quality. Bone turnover, mineralization, microarchitecture,
microfractures and matrix and mineral composition are all
important determinants of bone quality. A bone biopsy remains
at present a prerequisite for proper evaluation of bone quality.
Non-invasive analytical approaches such as biomarkers and iso-
tope and imaging techniques are available, but their clinical
utility in CKD is still being assessed. It is unlikely, however, that
these techniques will render bone biopsies obsolete in the
workup of low-impact fractures or unexplained bone pain in
the setting of advanced CKD (with or without a functioning
transplant). These techniques will complement rather than
replace bone biopsy as a diagnostic tool.
Here we present the results of a pan-European survey on the
use of bone biopsies in the management of ROD. We also pro-
pose the formation of a European network to facilitate research
and improve the management of ROD.
BONE BIOPSY PRACTICE PATTERN: A
EUROPEAN SURVEY
Despite being considered the gold standard in diagnosing renal
bone disease, bone biopsies are performed rather exceptionally
in daily clinical practice. To get a better insight into current
bone biopsy practice patterns and attitudes towards the proce-
dure across Europe, an electronic survey was sent out in May
2015 to all European members of the ERA-EDTA CKD-MBD
Working Group (n¼ 230), complemented by European opinion
leaders (n¼ 13). Seventy-eight invitees completed the survey,
corresponding to a response rate of 32%. All regions of Europe
were represented. The main activity of the respondents was clin-
ical nephrology (50%), followed by dialysis (26%), transplanta-
tion (9%) and research (9%). The majority of respondents
(89%) work in tertiary academic referral hospitals. The follow-
ing paragraphs summarize the main results of the survey.
Current practice patterns. Half of the respondents reported
having performed bone biopsies in the past 5 years; among
them, 27.2% performed bone biopsies for research purposes
only. Most respondents thus perform bone biopsies for clinical
purposes. The total number of bone biopsy procedures per
respondent over the last 5 years was low, being<10. In 58.9% of
the cases, nephrologists were in charge of the bone biopsy pro-
cedure. In other centres, bone biopsies were performed by sur-
geons (12.5%) or rheumatologists (5.4%). The (trans)iliac
horizontal approach was most commonly used (65.5%), fol-
lowed by the vertical approach (29.1%). Only a few (8.0%) per-
formed drill-assisted bone biopsies. Small (inner
diameter<5mm) and non-disposable trephine needles are
gaining in popularity (almost 40% penetrance) at the expense of
the large, non-disposable Bordier and Bedford trephine
needles. Most procedures (66.7%) were performed with
local anaesthesia in combination with light sedation (midazo-
lam). Histomorphometry was mostly performed in external
laboratories.
Indications. Most respondents agreed on the following bone
biopsy indications: low-impact fracture, unexplained bone pain,
prior to parathyroidectomy (to confirm high bone turnover) or
initiation of antiresorptive drugs (to exclude low bone turn-
over), unexplained hypercalcaemia or radiologic abnormality
and suspected or proven overload or toxicity to heavy or rare
metals. Also, a discordance between parathyroid hormone
(PTH) and alkaline phosphatase levels is considered an indica-
tion for a bone biopsy by almost 50% of the respondents. Most
respondents consider a stand-alone PTH level outside the
2 P. Evenepoel et al.
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KDIGO target range insufficient to proceed with a bone biopsy.
While a majority of respondents consider a bone biopsy valua-
ble to confirm high bone turnover before parathyroidectomy,
they mostly disagree with the statement that it should be per-
formed before initiating PTH suppressive therapy (calcimimet-
ics, active vitamin D analogues) (Figure 1).
Limitations/hurdles. Multiple hurdles hampering the wide-
spread implementation of bone biopsies were identified. These
included a laborious sampling procedure, time-consuming and
costly histopathological analysis and missing histopathological
expertise. Of the respondents, 51% state that procedural pain is
a hurdle to the widespread implementation of bone biopsy as a
diagnostic clinical tool (Figure 2). Of interest, most respondents
disagree with the statement that a bone biopsy is mainly a
research tool with little clinical added value.
In aggregate, the results of this survey teach us that a bone
biopsy overall is perceived as an invasive, painful, laborious but
clinically useful procedure and that histomorphometric exper-
tise is not widely available. Histomorphometry, moreover, is
complex, time-consuming and costly, all important hurdles in
an era in which cost savings and immediate feedback are
increasingly appreciated. Consequently, bone biopsies at
present are nowhere part of routine assessment and follow-up
and are performed in specific cases in a limited number of
centres only. A negative spiral is ongoing, which may finally
result in complete disappearance of the expertise.
THE EU-ROD INITIATIVE
In an attempt to halt this negative spiral the European Renal
Osteodystrophy (EU-ROD) initiative was created under the
umbrella of the ERA-EDTA CKD-MBD Working Group. EU-
ROD’s primary mission is to revitalize bone biopsy as a clini-
cally useful tool in the diagnostic workup of CKD-MBD and to
facilitate research on the epidemiology, implications and rever-
sibility of ROD.
A bone biopsy is deemed an interesting scientific tool [13],
but only seldom is it considered in daily clinical practice. The
perception of the clinical usefulness of a bone biopsy is often
negative, as less invasive and demanding approaches have
become available. In particular, the reduced procedural com-
plexity and morbidity related to the use of smaller and dispos-
able trephine needles may lower the threshold for performing a
bone biopsy. There is almost no trade-off, as most procedures
with these needles yield sufficient bone tissue for bone histo-
morphometry. Even more threatening for the survival of bone
biopsy as a diagnostic procedure is the vanishing reservoir of
experts in clinical histomorphometry. Both a low clinical
demand and budgetary restrictions erased interest in bone his-
tomorphometry for clinical purposes.
Today, epidemiological studies investigating the pattern of
ROD across stages of CKD and its evolution over the years are
FIGURE 1: Responses to statement: ‘Please indicate whether you agree or not following potential indications to perform a bone biopsy.’
Percentage distribution.
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sparse and often flawed by selection bias. Published data may
not be valid, given that a considerable proportion of biopsies
were retrieved during research projects. Also, regional differen-
ces in ethnic background, demographics and CKD-MBD treat-
ment may limit the applicability of global collaborative reports
for local health care practitioners. A European collaboration of
clinicians, specializing in treating bone disorders in CKD and in
retrieving bone biopsies in clinical settings, could result in more
valid epidemiological data.
Studies investigating the association between indices of bone
quality and prevalent and incident fractures are limited, if not
non-existent. An overarching cohort study combining
bone biopsy databases from different European centres would
offer a blueprint of contemporaneous renal bone disease in
Europe and may be hypothesized to offer hints to biological fac-
tors and mechanisms underlying the increased fracture risk in
CKD.
The armamentarium to tackle age-related osteoporosis is
rapidly expanding [14]. Clinical trials of senile osteoporosis
therapy generally exclude patients with advanced kidney dis-
ease. The lack of information with regards to the role, efficacy
and safety of established and novel agents for the treatment
of osteoporosis in these patients paves the way for therapeutic
nihilism. Post hoc analyses of large studies in post-meno-
pausal women showed a similar benefit in CKD patients as
in the general population. However, those CKD patients did
not have biochemical abnormalities associated with CKD-
MBD. Additional studies are urgently required to evaluate the
efficacy and safety of antiresorptive and anabolic agents in
the setting of CKD. A European collaborative effort offers the
best soil for initiating and successfully completing such inter-
vention studies.
After kidney transplantation, bone disorders often persist
due to incomplete recovery of pre-existing disturbances of min-
eral metabolism, de novo CKD-MBD due to reduced kidney
graft function and the negative effect of immunosuppression on
bone [15]. However, little is known about the association of
laboratory abnormalities with bone disorders, vascular pathol-
ogy and outcome after kidney transplantation. The few and
small bone biopsy studies that have been performed suggest a
poor association of circulating bone turnover markers and bone
histomorphometric findings and an increasing prevalence of
low bone turnover with time from transplantation [16–19]. The
EU-ROD initiative will facilitate further exploration of the path-
ophysiology of post-transplant CKD-MBD and enable the per-
formance of interventional studies aimed at treatment and
prevention of bone and vascular complications.
The aims of the EU-ROD initiative include the following:
1. To revitalize bone biopsy as a clinically useful tool in daily
practice. Bone biopsies should regain a prominent place in
daily practice to help tailor CKD-MBD therapy for indi-
vidual patients, a relevant goal in an era favouring person-
alized medicine. We envisage the following initiatives to
achieve this aim:
a. Organize hands-on workshops and training programs
for clinicians and pathologists to spread expertise in
the ﬁeld.
b. Harmonize the bone biopsy procedure, sample han-
dling and reading [standard operating procedures
(SOPs)]. Publish SOPs with regard to the bone biopsy
procedure, analysis and reporting.
c. Harmonize units of the various histomorphometric
parameters among histopathology labs to facilitate
comparison and interpretation of results.
d. Deﬁne normal ranges for static and dynamic histomor-
phometric parameters.
e. Report on the pattern of ROD in contemporaneous
European CKD patients.
2. To promote and organize pan-European research in the
ﬁeld of ROD. We foresee the following initiatives to
achieve this aim:
a. Create an online repository of existing European clini-
cal material and a network of investigators in the ﬁeld
of ROD.
FIGURE 2: Responses to question: ‘What are in your opinion hurdles to a more widespread clinical implementation of bone biopsies in CKD
patients?’ Percentage distribution.
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|b. Identify research questions that can be addressed by
pooling existing data once the repository is created.
These questions may relate to the epidemiology, impli-
cations and reversibility/treatment of ROD.
c. Develop SOPs for diagnosis, including the bone biopsy
procedure, analysis and reporting, (see above), circulat-
ing bone biomarkers and imaging techniques.
d. Although bone biopsy is considered the gold standard
for evaluating bone health, there is at present no proof
that bone histomorphometry outperforms clinical, bio-
chemical and radiological indices as a hard outcome
risk predictor. The present initiative will address the
question whether more frequent bone biopsies result in
a decreased fracture burden (and related morbidity and
mortality).
e. Search for a less demanding but equally relevant and
accurate analytical alternative to classical histomorph-
ometry for the diagnosis of ROD. Classical operator-
dependent histomorphometry is very laborious and
time consuming, curtailing ‘routine’ analysis.
Circulating bone-speciﬁc biomarkers [20], as well as
isotope [21] and imaging techniques (MRI, HR-pQCT,
18F-ﬂuoride positron emission tomography, etc.),
though promising non-invasive alternatives to bone
biopsy, so far do not provide information as precise as
that provided by bone histomorphometry in CKD.
Currently available bone biomarkers fail in distinguish-
ing low from normal bone turnover. Additional valida-
tion studies in larger cohorts with simultaneous bone
histomorphometry data across the whole spectrum of
CKD-MBD are mandatory.
f. To initiate and support clinical intervention studies
aimed at ameliorating ROD and fracture risk.
g. To facilitate fund raising for research at national and
European levels.
3. To improve and distribute knowledge in the ﬁeld of ROD.
We envisage the following initiatives to achieve this aim:
a. Collaborate with the European Best Practice Guideline
group in the updating process of guidelines related to
the care of ROD patients.
b. Collaborate with the ERA-EDTA Registry and
European Dialysis Outcomes and Practice Patterns
Study initiative to evaluate current practice patterns
with regard to the evaluation of ROD.
c. To collaborate on educational activities regarding ROD
within the ERA-EDTA (CKD-MBD Working Group),
including (i) organization of an annual working group
meeting, (ii) the preparation of position papers and
review articles on relevant ROD issues and (iii) the
organization of symposia (including workshops) spe-
ciﬁcally dedicated to ROD and by extension CKD-
MBD.
4. To closely collaborate and interact with similar initiatives
elsewhere in the world, e.g. the Brazilian Registry of Bone
Biopsy (Registro Brasileiro de Biopsias Osseas) [22].
5. To closely collaborate with other bone and mineral soci-
eties around the world.
CONCLUSION
It is time to halt the negative spiral of bone biopsy procedures.
Bone histomorphometry often remains indispensable in the
workup of low-impact fracture in the setting of advanced CKD,
which is a common complication among CKD patients. The
prevention and treatment of low-impact fractures in CKD
patients is challenging and at the same time it is frustrating
because of a lack of evidence. More widespread implementation
of bone biopsies as a diagnostic procedure may widen the thera-
peutic horizon and foster the development and validation of
more reliable, non-invasive diagnostic tools.
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